[go: up one dir, main page]

BRPI0606282A2 - composições injetáveis de compostos imunossupressores em nanopartìculas - Google Patents

composições injetáveis de compostos imunossupressores em nanopartìculas

Info

Publication number
BRPI0606282A2
BRPI0606282A2 BRPI0606282-2A BRPI0606282A BRPI0606282A2 BR PI0606282 A2 BRPI0606282 A2 BR PI0606282A2 BR PI0606282 A BRPI0606282 A BR PI0606282A BR PI0606282 A2 BRPI0606282 A2 BR PI0606282A2
Authority
BR
Brazil
Prior art keywords
nanoparticulate
tacrolimus
sirolimus
injectable
injectable compositions
Prior art date
Application number
BRPI0606282-2A
Other languages
English (en)
Inventor
Gary Liversidge
Scott Jenkins
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of BRPI0606282A2 publication Critical patent/BRPI0606282A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSIçõES INJETáVEIS DE COMPOSTOS IMUNOSSUPRESSORES EM NANOPARTìCULAS. A presente invenção refere-se a uma composição injetável de 'imunossupressores em nanopartículas para a fqrmaçáo de um depósito subcutâneo ou intramuscular. A invenção também se refere a uma composição injetável de tacrolimus e/ou sirolimus em nanopartículas a qual elimina a necessidade de usar óleo de rícino hidrogenado polioxil 60 (HCO-60) e/ou polissorbato 80 como um solubilizante. Esta invenção descreve adicionalmente um método para fabricar uma composição injetável de tacrolimus e/ou sirolimus em nanopartículas compreendendo tacrolimus, sirolimus, ou combinação dos mesmos para um depósito subcutâneo ou intramuscular para a profilaxia de rejeição de órgáo e para o tratamento de psoríase ou outras doenças imunes.
BRPI0606282-2A 2005-03-17 2006-03-16 composições injetáveis de compostos imunossupressores em nanopartìculas BRPI0606282A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66269205P 2005-03-17 2005-03-17
PCT/US2006/009510 WO2006101972A2 (en) 2005-03-17 2006-03-16 Injectable compositions of nanoparticulate immunosuppressive compounds

Publications (1)

Publication Number Publication Date
BRPI0606282A2 true BRPI0606282A2 (pt) 2009-06-09

Family

ID=36954386

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606282-2A BRPI0606282A2 (pt) 2005-03-17 2006-03-16 composições injetáveis de compostos imunossupressores em nanopartìculas

Country Status (14)

Country Link
US (1) US20060210638A1 (pt)
EP (1) EP1868576A2 (pt)
JP (1) JP2008533165A (pt)
KR (1) KR20070121758A (pt)
CN (1) CN101175481A (pt)
AU (1) AU2006227623B2 (pt)
BR (1) BRPI0606282A2 (pt)
CA (1) CA2601312A1 (pt)
EA (1) EA200701998A1 (pt)
IL (1) IL185952A0 (pt)
MX (1) MX2007011494A (pt)
NO (1) NO20075295L (pt)
WO (1) WO2006101972A2 (pt)
ZA (1) ZA200708458B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
PT1663217E (pt) * 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
AU2004267910B2 (en) 2003-08-29 2011-01-06 Veloxis Pharmaceuticals, Inc. Solid dispersions comprising tacrolimus
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007127363A2 (en) 2006-04-26 2007-11-08 Micell Technologies, Inc. Coatings containing multiple drugs
JP2009538927A (ja) 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
JP5336382B2 (ja) 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
EP1938800A1 (en) * 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
ES2435197T3 (es) * 2007-01-10 2013-12-16 Board Of Regents, The University Of Texas System Administración mejorada de composiciones de fármacos inmunosupresores para la administración por vía pulmonar
EP2131821B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
EP2170418B1 (en) 2007-05-25 2016-03-16 Micell Technologies, Inc. Polymer films for medical device coating
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
DK2167033T3 (en) 2007-05-30 2017-08-14 Veloxis Pharmaceuticals As Once daily oral dosage form comprising tacrolism
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
CN102083397B (zh) 2008-04-17 2013-12-25 米歇尔技术公司 具有生物可吸收层的支架
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
EP2575769B1 (en) 2010-02-17 2016-06-15 Veloxis Pharmaceuticals A/S Stabilized tacrolimus composition
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) * 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
EA201790045A1 (ru) 2011-04-29 2017-09-29 Селекта Байосайенсиз, Инк. Наноносители, вырабатывающие имунную толерантность, для антиген-специфического удаления т-эффекторных клеток
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US8716363B2 (en) * 2011-09-28 2014-05-06 Globus Medical, Inc. Biodegradable putty compositions and implant devices, methods, and kits relating to the same
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN105188753B (zh) 2012-11-08 2018-12-18 国立大学法人山口大学 角结膜病症的治疗剂
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
KR20150123838A (ko) * 2013-03-04 2015-11-04 브이티브이 테라퓨틱스 엘엘씨 안정한 글루코키나제 활성화제 조성물
CA2905419C (en) 2013-03-12 2020-04-28 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
EP2991631A4 (en) * 2013-05-03 2016-11-16 Selecta Biosciences Inc TOLEROGENIC SYNTHETIC NANOTRANS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR IMPROVED PHARMACODYNAMIC EFFECTS
KR102079613B1 (ko) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
EP3000466B1 (en) * 2013-05-22 2018-08-15 Yamaguchi University Inhibitor for retinochoroidal disorders
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
KR20160120739A (ko) * 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
DK3125875T3 (da) 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
BR112017001311A2 (pt) 2014-09-07 2017-11-14 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon
EP3209330B1 (en) 2014-10-07 2022-02-23 AI Therapeutics, Inc. An inhalable sirolimus formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
US11260027B2 (en) 2015-07-29 2022-03-01 Musc Foundation For Research Development Donor organ pre-treatment formulation
CN105267146B (zh) * 2015-11-25 2018-03-13 华北制药集团新药研究开发有限责任公司 一种无菌他克莫司纳米混悬滴眼液的制备方法
EP4249490A3 (en) 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
CA3043807A1 (en) 2016-11-16 2018-05-24 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)
US10722499B2 (en) 2017-01-06 2020-07-28 Palvella Therapeutics, Inc. Anyhydrous compositions of mTOR inhibitors and methods of use
AU2018236123B2 (en) 2017-03-11 2024-04-18 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2018321744A1 (en) 2017-08-24 2020-04-02 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
CN108383856B (zh) * 2018-05-25 2020-03-27 中国医学科学院生物医学工程研究所 他克莫司纳米晶及其人工泪液复合物与制备方法
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
US20200038560A1 (en) * 2018-07-31 2020-02-06 Cook Medical Technologies Llc Limus coatings and methods of use thereof
CN112791066B (zh) * 2019-11-13 2024-04-02 鲁南制药集团股份有限公司 一种注射用西罗莫司缓释微球及其制备方法
CN111450064A (zh) * 2020-04-09 2020-07-28 广州中医药大学(广州中医药研究院) 基于超临界反溶剂法制备西罗莫司包覆颗粒的方法及其制得的西罗莫司包覆颗粒和应用
EP4014963A1 (en) 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
WO2022266251A1 (en) * 2021-06-16 2022-12-22 The Board Of Trustees Of The Leland Stanford Junior University Compositions for treatment of psoriasis
GB2612779A (en) 2021-11-10 2023-05-17 Pharmathen Sa Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
MX2024003886A (es) 2021-09-27 2024-07-10 Pharmathen Sa Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso.
CN114642663A (zh) * 2022-03-29 2022-06-21 江苏杜瑞制药有限公司 一种稳定的他克莫司药物组合物及其制备方法和应用
CN117797093A (zh) * 2024-02-29 2024-04-02 中国农业科学院农业环境与可持续发展研究所 一种以大环内酯类药物为活性成分的兽用口服纳米液体制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
JP3714970B2 (ja) * 1998-03-26 2005-11-09 アステラス製薬株式会社 徐放性製剤
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
CN100512798C (zh) * 2000-12-22 2009-07-15 巴克斯特国际公司 亚微米颗粒悬浮液制备方法
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
PT1663217E (pt) * 2003-08-29 2010-10-18 Lifecycle Pharma As Dispersão sólida que compreende tacromílus
AU2004267910B2 (en) * 2003-08-29 2011-01-06 Veloxis Pharmaceuticals, Inc. Solid dispersions comprising tacrolimus
MX2007007342A (es) * 2004-12-15 2007-12-11 Elan Pharma Int Ltd Formulaciones de tacrolimus nanoparticuladas.

Also Published As

Publication number Publication date
ZA200708458B (en) 2009-05-27
JP2008533165A (ja) 2008-08-21
WO2006101972A2 (en) 2006-09-28
EP1868576A2 (en) 2007-12-26
EA200701998A1 (ru) 2008-02-28
MX2007011494A (es) 2007-12-06
AU2006227623B2 (en) 2011-10-20
NO20075295L (no) 2007-11-29
CN101175481A (zh) 2008-05-07
CA2601312A1 (en) 2006-09-28
WO2006101972A3 (en) 2006-12-07
AU2006227623A1 (en) 2006-09-28
IL185952A0 (en) 2008-01-06
KR20070121758A (ko) 2007-12-27
US20060210638A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
BRPI0606282A2 (pt) composições injetáveis de compostos imunossupressores em nanopartìculas
WO2008092006A3 (en) Antimicrobial compositions
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
CY1120137T1 (el) Ενεσιμα σκευασματα βοτουλινικης τοξινης
WO2008115974A3 (en) Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
CO6501147A2 (es) Inhibidores de mtor cinasa para indicadores de oncología y enfermedades asociadas con la trayectoria mtor/pi3k/akt
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
PE20121181A1 (es) Inhibidor de bromodominio de benzodiazepina
CR10458A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
EP3150635A3 (en) Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
MX2008002345A (es) Formulaciones inyectables de larga accion.
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
NZ596388A (en) Thiazole derivatives and their use as p2y12 receptor antagonists
WO2008003978A3 (en) Dioxo-alkanes and dioxo-alkenes
AR074379A1 (es) Inhibidor de triazolotiadiazola de la proteina quinasa c-met
AR059320A1 (es) Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico
NO20074722L (no) Anvendelse av en epidermal vekstfaktor reseptor kinase inhibitor (EGRR) i gefitinib resistente pasienter
WO2009043987A9 (fr) Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales
WO2007130848A3 (en) Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
NZ770290A (en) Methods and compositions for treating pulmonary hypertension
AR071309A1 (es) Metodos para tratar cancer y equipo con una combinacion que comprende un anticuerpo l2g7 humanizado y un agonista pten
AR072759A1 (es) Una combinacion sinergica de un anticuerpo anti-egfr y un inmunosupresor, composicion farmaceutica y procedimiento para obtenerla, metodo de deteccion, uso y kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013.